Antiplatelet Therapy And Percutaneous Coronary Interventions

Area of Science:

• Cardiovascular Medicine
• Interventional Cardiology
• Pharmacology

Background:

• Dual antiplatelet therapy (DAPT) is fundamental in percutaneous coronary interventions (PCI).
• New antiplatelet agents reduce ischemic events but increase bleeding risks.
• Optimizing DAPT aims to maximize anti-thrombotic benefits while minimizing bleeding complications for improved net clinical benefit.

Purpose of the Study:

• To provide an updated literature review on DAPT in patients undergoing coronary angioplasty and stenting.
• To discuss strategies for optimizing DAPT to enhance net clinical benefit.
• To address challenges in translating clinical trial results into practice due to therapeutic heterogeneity.

Main Methods:

• Systematic review of recent clinical trials and studies on DAPT in PCI.
• Analysis of data concerning different drug combinations and treatment durations.
• Evaluation of factors influencing the balance between ischemic and bleeding events.

Main Results:

• Multiple trials have investigated various DAPT regimens and durations.
• Evidence suggests a complex interplay between antiplatelet efficacy and bleeding risk.
• Heterogeneity in trial methodologies complicates direct clinical application.

Conclusions:

• Optimizing DAPT remains a critical goal in interventional cardiology.
• Further research is needed to standardize therapeutic approaches and improve clinical outcomes.
• Personalized DAPT strategies are essential for maximizing net clinical benefit in PCI patients.